Cancer is the most common cause of death from disease in children. Neuroblastoma is a solid tumor in early childhood. Despite multimodality therapy, the majority of high-risk neuroblastoma patients die of the disease, and survivors suffer from long-term disabilities due to adverse side effects from chemo- and radiotherapy at an early age. There is an urgent need to better understand its tumorigenesis and to identify novel therapies.
The focus areas: (1) Therapy, and (2) Biology and Etiology.
In this project, we aim to define a novel RNA methyltransferase as a critical driver of neuroblastoma progression, to identify small molecule inhibitors of the novel RNA methyltransferase, and to demonstrate their anticancer efficacy. Successful completion of this project will provide a novel targeted therapy for potential clinical translation in patients with the rare but deadly neuroblastoma. | 
